博安生物(06955.HK)BA1104中國三期臨床試驗完成首例患者入組
博安生物(06955.HK)公布,集團旗下納武利尤單抗注射液(BA1104)在中國開展的三期臨床試驗,近日已完成首例患者入組,預期該產品是中國首個開展三期臨床試驗的歐狄沃(Opdivo)生物類似藥。
博安生物表示,在龐大未滿足的臨床需求以及明確的臨床價值等因素的驅動下,預期BA1104將具有廣闊的市場前景,未來會積極探索該產品與其他創新抗體在研藥物的聯合治療潛力,包括與創新免疫檢查點抑制劑BA1106、抗體偶聯藥物BA1301和雙特異性抗體BA1202等藥物的聯合開發。(gc/s)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.